Teriparatide as a Chondroregenerative Therapy in OA

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Knee OsteoarthritisCartilage Degeneration
Interventions
DRUG

Teriparatide

20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.

DRUG

Placebo

20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.

Trial Locations (1)

14618

URMC Orthopaedics, Clinton Crossings Building D, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

University of Rochester

OTHER

collaborator

Duke University

OTHER

collaborator

Milton S. Hershey Medical Center

OTHER

lead

Christopher Ritchlin

OTHER